**Highlights of This Issue** 5259

**SPECIAL FEATURES**

**CCR Translations**

5261 | Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity
Aurélien Marabelle, Holbrook Kohrt, and Ronald Levy
*See related article, p 5381*

**CCR New Strategies**

5264 | New Strategies in Endometrial Cancer: Targeting the PI3K/mTOR Pathway—The Devil Is in the Details
Andrea P. Myers

**Molecular Pathways**

5275 | Molecular Pathways: MERTK Signaling in Cancer
Christopher T. Cummings, Deborah DeRyckere, H. Shelton Earp, and Douglas K. Graham

**CCR Focus**

5282 | A Sea Change in Melanoma
Susan E. Bates

5283 | The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be
Ryan J. Sullivan, Patricia M. LoRusso, and Keith T. Flaherty

5292 | Adoptive T-cell Transfer Therapy and Oncogene-Targeted Therapy for Melanoma: The Search for Synergy
Mei Li M. Kwong, Bart Neyns, and James C. Yang

5300 | CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
Patrick A. Ott, F. Stephen Hodi, and Caroline Robert

5310 | Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma
Lawrence N. Kwong and Michael A. Davies

**HUMAN CANCER BIOLOGY**

5320 | The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Karen E. Sheppard and Grant A. McArthur

5329 | Novel Clinically Relevant Genes in Gastrointestinal Stromal Tumors Identified by Exome Sequencing
Sebastian F. Schoppmann, Ursula Vinatzer, Niko Popitsch, Martina Mittlbock, Sandra Liebmann-Reindl, Gerd Jomrich, Berthold Streubel, and Peter Birner

5340 | Characterization of CD145+/CD31+/CD105+ Circulating Cells in the Peripheral Blood of Patients with Gynecologic Malignancies

5351 | Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers
Olga K. Afanasiev, Lola Yelistratova, Natalie Miller, Kotaro Nagase, Kelly Paulson, Jayasri G. Iyer, Dafina Ibrani, David M. Koelle, and Paul Nghiem

5361 | Characterization and Clinical Relevance of ALDHbright Populations in Prostate Cancer
Clémantine Le Magnen, Lukas Bubendorf, Cyrill A. Rentsch, Chantal Mengus, Joel Gispener, Tobias Zellweger, Malte Rieken, George N. Thalmann, Marco G. Cecchini, Markus Germann, Alexander Bachmann, Stephen Wyler, Michael Heberer, and Giulio C. Spagnoli

5372 | Prognostic Significance of AMPK Activation and Therapeutic Effects of Metformin in Hepatocellular Carcinoma
Longyi Zheng, Wen Yang, Fuquan Wu, Chao Wang, Lexing Yu, Liang Tang, Bijun Qiu, Yuqiong Li, Linna Guo, Mengchao Wu, Gensheng Feng, Dajin Zou, and Hongyang Wang
CANCER THERAPY: PRECLINICAL

5381 Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8⁺ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
Marieke F. Fransen, Tetje C. van der Sluis, Ferry Ossendorp, Ramon Arens, and Cornelis J.M. Melief
See related article, p 5261

5390 Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
Brent N. Rexer, Ritwik Ghosh, Archana Narasanna, Mónica Valeria Estrada, Anindita Chakrabarty, Youngchul Song, Jeffrey A. Engelman, and Carlos L. Arteaga

5402 The Integrin Inhibitor Cilengitide Affects Meningioma Cell Motility and Invasion
Annette Wilisch-Neumann, Nadine Kliese, Doreen Pachow, Thomas Schneider, Jan-Peter Warnke, Werner EK Braunsdorf, Frank-Dietmar Böhm, Peter Hass, Diana Pasmann, Cornelia Helbing, Elmar Kirches, and Christian Mawrin

5413 PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System
Julia A. Beaver, John P. Gustin, Kyung H. Yi, Anindita Chakrabarty, Matthew Thomas, Samuel F. Gilbert, D. Marc Rosen, Ben Ho Park, and Josh Lauring

IMAGING, DIAGNOSIS, PROGNOSIS

5423 MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma
Wei Meng, Zhengqing Ye, Ri Cui, James Perry, Vaia Dedousi-Huebner, Alexander Huebner, Yao Wang, Bin Li, Stefano Volinia, Hiroshi Nakanishi, Taewon Kim, Sung-Suk Suh, Leona W. Ayers, Patrick Ross, Carlo M. Croce, Arnas Chakravartii, Victor X. Jin, and Tim Lautenschlaeger

CANCER THERAPY: CLINICAL

In Vivo Imaging of Prostate Cancer Using [⁶⁸Ga]-Labeled Bombesin Analog BAY86-7548

Unique DNA Methylation Loci Distinguish Anatomic Site and HPV Status in Head and Neck Squamous Cell Carcinoma
Roberto A. Lleras, Richard V. Smith, Leslie R. Adrien, Nicolas F. Schlecht, Robert D. Burk, Thomas M. Harris, Geoffrey Childs, Michael B. Prystowsky, and Thomas J. Belbin

Prognostic Factors in Patients with Advanced Cancer: A Comparison of Clinicopathological Factors and the Development of an Inflammation-Based Prognostic System
Barry J. Laird, Stein Kaasa, Donald C. McMillan, Marie T. Fallon, Marianne J. Hjermstad, Peter Fayers, and Pal Klepstad

HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virus–Related Hepatocellular Carcinoma
Elisabetta Cariani, Massimo Pilli, Alessandro Zerbini, Cristina Rota, Andrea Olivani, Paola Zanelli, Adele Zanetti, Tommaso Trenti, Carlo Ferrari, and Gabriele Missale

Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial
Ana M. Gonzalez-Angulo, Funda Meric-Bernstam, Sant Chawla, Gerald Falchook, David Hong, Argun Akcakanat, Huejic Chen, Aung Naing, Siqing Fu, Jennifer Wheeler, Stacy Moulder, Thorunn Helgason, Shaoyi Li, Ileana Elias, Neel Desai, and Razelle Kurzrock

Clinical Cancer Research
ABOUT THE COVER

Metformin administration significantly inhibited the growth of SMMC7721 cell-derived tumor xenografts in nude mice. The cover shows hematoxylin and eosin staining of the tumor tissue from control mice. For details, see the article by Zheng and colleagues on page 5372 of this issue.